Reducing data variability means increasing trial power, improving data analysis and empowering decision-making. It means that clinical trials need to be repeated less often. It means that drug programs are more likely to succeed. Most importantly, it means assuring and accelerating the delivery of medicines to patients.
De-Risk Drug Development
The pharmaceutical, biotechnology and medical device industries have been plagued by high rates of failure in Phase 2 and Phase 3 due to the inability to demonstrate therapeutic efficacy. Over time, this has resulted in clinical trials that are longer, more expensive and more burdensome for patients. It has also resulted in the premature discontinuation of the development of efficacious drugs. Tools4Patient has developed platform technologies that address key sources of data variability to improve the success rate of clinical trials and de-risk the drug development process.
Latest News and Events from Tools4Patient
STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October 13, 2020. TheFind out more...
Reducing clinical data variability. Empowering better decision making. Accelerating the launch of therapeutics to market.